Citius Pharmaceuticals’ lymphir Phase 1 trial adds City of Hope site

Citius Pharmaceuticals announced that the University of Minnesota Masonic Cancer Center intends to expand their ongoing investigator-initiated Phase 1 trial of Lymphir in combination with FDA-approved CAR-T products for the treatment of B-cell lymphomas. The ongoing study will include an additional study site at City of Hope, a cancer treatment and research institution and one of 53 National Cancer Institute-designated comprehensive cancer centers in the U.S. This Phase 1 dose-finding study to evaluate Lymphir prior to CAR-T therapies tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel, in patients with B-cell lymphomas was initiated in May 2021 and has been expanded to include City of Hope.